Tevogen (TVGN) Cash from Financing Activities (2023 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Cash from Financing Activities came in at $2.9 million in Q1 2026, down 28.16% YoY from $4.0 million in Q1 2025, and up 63.19% on a QoQ basis from $1.8 million in Q4 2025.
Tevogen (TVGN) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 4 years of Cash from Financing Activities data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 28.16% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 23.65% YoY) and the FY2025 annual result came in at $11.7 million, down 4.64% from the prior year.
- Cash from Financing Activities climbed to $2.9 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $5.0 million in Q3 2024 to a low of $422250.0 in Q4 2023.
- A 4-year average of $2.6 million and a median of $2.5 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 426.32% — and 2025, when it slumped 32.14%.
- Tracing TVGN's Cash from Financing Activities over 4 years: stood at $422250.0 in 2023, then surged by 373.65% to $2.0 million in 2024, then decreased by 11.95% to $1.8 million in 2025, then surged by 63.19% to $2.9 million in 2026.
- The last three Cash from Financing Activities figures came in at $2.9 million (Q1 2026), $1.8 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 2.43 Mn |
| Mar 31, 2024 | 2.43 Mn |
| Dec 31, 2023 | 422,250.00 |
| Dec 31, 2023 | 422,250.00 |